anti‐TNF therapy—a double‐edged sword?
P Schreiner, L Biedermann - Alimentary pharmacology & …, 2019 - search.ebscohost.com
Editorial: anti‐TNF therapy—a double‐edged sword? Page 1 822 | wileyonlinelibrary.com/journal/apt
Aliment Pharmacol Ther. 2019;50:822–833. © 2019 John Wiley & Sons Ltd DOI: 10.1111/apt.15401 …
Aliment Pharmacol Ther. 2019;50:822–833. © 2019 John Wiley & Sons Ltd DOI: 10.1111/apt.15401 …
[HTML][HTML] Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad …
Y González-Lama, J Sanz, G Bastida, J Campos… - Gastroenterología y …, 2020 - Elsevier
Las manifestaciones extraintestinales en general, y entre ellas las articulares en particular,
suponen un problema frecuente en los pacientes con enfermedad inflamatoria intestinal. De …
suponen un problema frecuente en los pacientes con enfermedad inflamatoria intestinal. De …
Crohn's disease diagnosis during adalimumab treatment
L Fernández Salazar, J Barrio Andrés… - Scandinavian Journal …, 2013 - Taylor & Francis
IBD flares or new diagnosis in patients receiving anti-TNF because of other diseases than
IBD are rare events but the possibility of a paradoxical reaction must be considered as with …
IBD are rare events but the possibility of a paradoxical reaction must be considered as with …
Infliximab induces a dysregulated tissue-homing profile on human T-lymphocytes in-vitro: A novel mechanism for paradoxical inflammation?
ST Peake, D Bernardo, ER Mann… - Journal of Crohn's …, 2013 - academic.oup.com
Paradoxical inflammation (PI) is defined as the development of inflammatory lesions in
patients with immune mediated inflammatory disease after initiation of treatment with anti …
patients with immune mediated inflammatory disease after initiation of treatment with anti …
Несвоевременные мысли о применении генно-инженерных биологических препаратов при ревматических болезнях
ЮВ Муравьев, ЛА Муравьева - Научно-практическая …, 2016 - cyberleninka.ru
В течение последних двух десятилетий разработан целый ряд инновационных генно-
инженерных биологических препаратов, внедрение которых в клиническую практику …
инженерных биологических препаратов, внедрение которых в клиническую практику …
Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases
I Trivedi, SB Hanauer - Expert Opinion on Drug Safety, 2015 - Taylor & Francis
Introduction: The incidence of Inflammatory Bowel Diseases (IBD) is rising and overall
epidemiology is changing. Goals of IBD therapy are also fast changing to reflect the concept …
epidemiology is changing. Goals of IBD therapy are also fast changing to reflect the concept …
Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
J Sellam, J Morel, A Tournadre, Y Bouhnik… - Joint bone …, 2021 - pubmed.ncbi.nlm.nih.gov
PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by
the Club Rhumatismes et Inflammation (CRI) PRACTICAL MANAGEMENT of patients on …
the Club Rhumatismes et Inflammation (CRI) PRACTICAL MANAGEMENT of patients on …
Paradoxical gastrointestinal reactions in patients taking tumor necrosis factor inhibitors: a rare event that broadens the histologic spectrum of medication–associated …
D Hutchings, JA Miller, L Voltaggio - Human pathology, 2019 - Elsevier
Tumor necrosis factor (TNF) inhibitors are widely used in the therapy of certain autoimmune
disorders. Paradoxical immunologic reactions manifesting as new-onset autoimmune …
disorders. Paradoxical immunologic reactions manifesting as new-onset autoimmune …
[HTML][HTML] New onset, aggravation and recurrence of Crohn's disease upon treatment with three different tumor necrosis factor inhibitors
J Zeitz, S Enderlin, L Biedermann, M Turina… - Case reports in …, 2015 - karger.com
Tumor necrosis factor (TNF) is a major cytokine in the pathogenesis of inflammatory bowel
disease (IBD), and TNF inhibition is a cornerstone of contemporary IBD therapy. However …
disease (IBD), and TNF inhibition is a cornerstone of contemporary IBD therapy. However …
The risk of inflammatory bowel disease in patients with axial spondyloarthritis treated with biologic agents: BSRBR-AS and meta-analysis
GJ Macfarlane, R Biallas, LE Dean, GT Jones… - The Journal of …, 2022 - jrheum.org
Objective To determine, among patients with axial spondyloarthritis (axSpA), whether the
risk of inflammatory bowel disease (IBD) varies between patients treated with biologic …
risk of inflammatory bowel disease (IBD) varies between patients treated with biologic …